The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial
Abstract
Background Afatinib, an irreversible ErbB-family blocker, has shown preclinical activity when tested in EGFR mutant models with mutations that confer resistance to EGFR tyrosine-kinase inhibitors. We aimed to assess its efficacy in patients with advanced lung adenocarcinoma with previous treatment failure on EGFR tyrosine-kinase inhibitors.Methods In this phase 2b/3 trial, we enrolled patients with stage IIIB or IV adenocarcinoma and an Eastern Cooperative Oncology Group performance (ECOG) performance score of 0-2 who had received one or two previous chemotherapy regimens and had disease progression after at least 12 weeks of treatment with erlotinib or gefitinib. We used a computer-generated sequence to randomly allocate patients (2:1) to either afatinib (50 mg per day) or placebo; all patients received best supportive care. Randomisation was done in blocks of three and was stratified by sex and baseline ECOG performance status (0-1 vs 2). Investigators, patients, and the trial sponsor were masked to treatment assignment. The primary endpoint was overall survival (from date of randomisation to death), analysed on an intention-to-treat basis. This study is registered with ClinicalTrials.gov, number NCT00656136.Findings Between May 26, 2008, and Sept 21, 2009, we identified 697 patients, 585 of whom were randomly allocated to treatment (390 to afatinib, 195 to placebo). Median overall survival was 10·8 months (95% CI 10·0-12·0) in the afatinib group and 12·0 months (10·2-14·3) in the placebo group (hazard ratio 1·08, 95% CI 0·86-1·35; p=0·74). Median progression-free survival was longer in the afatinib group (3·3 months, 95% CI 2·79-4·40) than it was in the placebo group (1·1 months, 0·95-1·68; hazard ratio 0·38, 95% CI 0·31-0·48; p<0·0001). No complete responses to treatment were noted; 29 (7%) patients had a partial response in the afatinib group, as did one patient in the placebo group. Subsequent cancer treatment was given to 257 (68%) patients in the afatinib group and 153 (79%) patients in the placebo group. The most common adverse events in the afatinib group were diarrhoea (339 [87%] of 390 patients; 66 [17%] were grade 3) and rash or acne (305 [78%] patients; 56 [14%] were grade 3). These events occurred less often in the placebo group (18 [9%] of 195 patients had diarrhoea; 31 [16%] had rash or acne), all being grade 1 or 2. Drug-related serious adverse events occurred in 39 (10%) patients in the afatinib group and one (<1%) patient in the placebo group. We recorded two possibly treatment-related deaths in the afatinib group.Interpretation Although we recorded no benefit in terms of overall survival with afatinib (which might have been affected by cancer treatments given after progression in both groups), our findings for progression-free survival and response to treatment suggest that afatinib could be of some benefit to patients with advanced lung adenocarcinoma who have failed at least 12 weeks of previous EGFR tyrosine-kinase inhibitor treatment.Funding Boehringer Ingelheim Inc.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“However, as monotherapy, they have failed to overcome T790M-mediated resistance in patients (28, 29), because concentrations at which these irreversible TKIs overcome T790M activity pre-clinically are not achievable in humans due to dose-limiting toxicity related to non-selective inhibition of wild-type EGFR (30).”
From AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer (2014) · cites this paper as [28]
In the citing paper
“However, we know from clinical experience that afatinib is unable to inhibit T790M in the clinic due to a lack of a therapeutic window”
In the citing paper
“For example, studies of afatinib monotherapy showed a response rate of less than 10% among patients with acquired resistance to erlotinib or gefitinib, with a progression-free survival of approximately 4 months.13,15”
From Rociletinib in EGFR-Mutated Non–Small-Cell Lung Cancer (2015) · cites this paper as [13]
In the citing paper
“However, in lung cancer patients, afatinib is only effective in EGFR TKI naive EGFR mutant cancers and has a RR of < 10% in patients with NSCLC that have developed resistance to gefitinib or erlotinib (13).”
From EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors (2015) · cites this paper as [13]
In the citing paper
“neither Afatinib [76] nor Neratinib [77] nor Dacomitinib [78] demonstrated significant activity as single agent in patients harboring the T790M mutations.”
From A decade of EGFR inhibition in EGFR-mutated non small cell lung cancer (NSCLC): Old successes and future perspectives (2015) · cites this paper as [76]
In the citing paper
“However, for EGFR T790M mutated lung cancer, it failed to overcome EGFR T790M-mediated resistance in patients [36, 37].”
In the citing paper
“Sixty-three percent of the patients in the afatinib group and 76% in the control group received ≥ one subsequent regimen (all mutation statuses).15”
From Systemic Therapy for Stage IV Non–Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update (2015) · cites this paper as [15]
In the citing paper
“Response rate was 7% versus 0.5%.”
From Systemic Therapy for Stage IV Non–Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update (2015) · cites this paper as [15]
In the citing paper
“In a prespecified analysis, participants with a complete or partial response to a first-line EGFR TKI whose tumors also had known EGFR mutation test results (58 [88%] of 66), the HR for PFS was significant (0.23), but the HR for OS was not (0.90) in the afatinib arm.”
From Systemic Therapy for Stage IV Non–Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update (2015) · cites this paper as [15]
In the citing paper
“Some of the second-line studies included patients who had received > two previous regimens.15,23,47,48,51,65”
From Systemic Therapy for Stage IV Non–Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update (2015) · cites this paper as [15]
In the citing paper
“The study found no improvement in the primary end point of OS between patients randomly assigned to afatinib and those randomly assigned to placebo, although PFS was longer in the afatinib group (3.3 v 1.1 months; HR, 0.38; 95% CI, 0.31 to 0.48; P < .001).”
From Systemic Therapy for Stage IV Non–Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update (2015) · cites this paper as [15]
In the citing paper
“Among these 96 patients, PFS was 3.3 months for those who received afatinib and 1.0 month for those who received placebo (HR, 0.55; 95% CI, 0.31 to 0.85; P = .009).15”
From Systemic Therapy for Stage IV Non–Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update (2015) · cites this paper as [15]
Citations
Cites
Aaronson, N. K., Ahmedzai, S., Bergman, B., Bullinger, M., Cull, A., Duez, N. J., Filiberti, A., Flechtner, H., Fleishman, S. B., Haes, J. C. J. M. D., et al. (1993) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/85.5.365 · Cited by 16,005
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
Mok, T. S., Wu, Y.-L., Thongprasert, S., Yang, C.-H., Chu, D.-T., Saijo, N., Sunpaweravong, P., Han, B., Margono, B., Ichinose, Y., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810699 · Cited by 8,261
Self-citationErlotinib in Previously Treated Non–Small-Cell Lung Cancer
Shepherd, F. A., Rodrigues Pereira, J., Ciuleanu, T., Tan, E. H., Hirsh, V., Thongprasert, S., Campos, D., Maoleekoonpiroj, S., Smylie, M., Martins, R., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050753 · Cited by 5,419
Self-citationScagliotti, G. V., Parikh, P., von Pawel, J., Biesma, B., Vansteenkiste, J., Manegold, C., Serwatowski, P., Gatzemeier, U., Digumarti, R., Zukin, M., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.0375 · Cited by 3,203
Self-citationFayers, P. M., Aaronson, N. K., Bjordal, K., Groenvold, M., Curran, D., & Bottomley, A. (2001) · Research at the University of Copenhagen (University of Copenhagen) · Cited by 2,520
BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models
Li, D., Ambrogio, L., Shimamura, T., Kubo, S., Takahashi, M., Chirieac, L. R., Padera, R. F., Shapiro, G. I., Baum, A., Himmelsbach, F., et al. (2008) · Oncogene · doi:10.1038/onc.2008.109 · Cited by 1,447
Pirker, R., Pereira, J. R., Szczęsna, A., von Pawel, J., Krzakowski, M. J., Ramlau, R., Vynnychenko, I. O., Park, K., Yu, C.-T., Ganul, V., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60569-9 · Cited by 1,346
Self-citationRational, biologically based treatment of EGFR-mutant non-small-cell lung cancer
Pao, W., & Chmielecki, J. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2947 · Cited by 1,083
Bergman, B., Aaronson, N. K., Ahmedzai, S. H., Kaasa, S., & Sullivan, M. (1994) · European Journal of Cancer · doi:10.1016/0959-8049(94)90535-5 · Cited by 906
Robins, J. M., & Finkelstein, D. M. (2000) · Biometrics · doi:10.1111/j.0006-341x.2000.00779.x · Cited by 877
Research works printed but not linked: 2
- Hirsh, 2011, Symptom and health-related quality of life benefit from afatinib (BIBW 2992) in advanced NSCLC patients previously treated with erlotinib or gefitinib: results of a randomized phase III study (LUX-Lung 1), Proc World Conf Lung Cancer
- Atagi, 2011, LUX-Lung 4: A phase II trial of afatinib (BIBW 2992) in advanced NSCLC patients previously treated with erlotinib or gefitinib, Proc World Conf Lung Cancer
Cited by
Sorted by citations
Items 401–500 of 988
Santoni, M., Conti, A., Andrikou, K., Bittoni, A., Lanese, A., Pistelli, M., Pantano, F., Vincenzi, B., Armento, G., Massari, F., et al. (2015) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2015.05.007 · Cited by 27
Afatinib combined with cetuximab for lung adenocarcinoma with leptomeningeal carcinomatosis
Lin, C.-H., Lin, M., Kuo, Y.-W., & Ho, C. (2014) · Lung Cancer · doi:10.1016/j.lungcan.2014.06.002 · Cited by 27
Brueckl, W. M., Tufman, A., & Huber, R. M. (2016) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2017.1266265 · Cited by 27
Emerging protein kinase inhibitors for non-small cell lung cancer
Liu, S. V., Subramaniam, D. S., Cyriac, G., Khalek, F. J. A., & Giaccone, G. (2013) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.2014.873403 · Cited by 28
Griebsch, I., Palmer, M. K., Fayers, P. M., & Ellis, S. H. (2014) · BMJ Open · doi:10.1136/bmjopen-2014-005762 · Cited by 27
Zhang, J., Zhang, Y., Tang, S., Jiang, L., He, Q., Hamblin, L. T., He, J., Wu, J., Wu, J., Chen, Y., et al. (2018) · BMJ Open · doi:10.1136/bmjopen-2017-017240 · Cited by 27
Self-citationTanaka, H., Taima, K., Itoga, M., Ishioka, Y., Baba, K., Shiratori, T., Sakamoto, H., Tsuchiya, J., Nakagawa, H., Hasegawa, Y., et al. (2019) · Medical Oncology · doi:10.1007/s12032-019-1278-9 · Cited by 27
Zhou, S., Kishi, N., Alerasool, P., & Rohs, N. C. (2024) · Targeted Oncology · doi:10.1007/s11523-024-01073-w · Cited by 30
Epidermal growth factor receptor tyrosine kinase inhibitors for non-small cell lung cancer
Asami, K. (2014) · World Journal of Clinical Oncology · doi:10.5306/wjco.v5.i4.646 · Cited by 25
EGFR Tyrosine Kinase Inhibitors: Difference in Efficacy and Resistance
Robinson, K. W., & Sandler, A. B. (2013) · Current Oncology Reports · doi:10.1007/s11912-013-0323-7 · Cited by 26
Secondary Resistant Mutations to Small Molecule Inhibitors in Cancer Cells
Hamid, A. B., & Petreaca, R. C. (2020) · Cancers · doi:10.3390/cancers12040927 · Cited by 29
Targeted Therapy for Non-Small Cell Lung Cancer
Noor, Z. S., Cummings, A. L., Johnson, M. M., Spiegel, M. L., & Goldman, J. W. (2020) · Seminars in Respiratory and Critical Care Medicine · doi:10.1055/s-0039-1700994 · Cited by 27
Gaut, D. L., Sim, M., Yue, Y., Wolf, B. R., Abarca, P. A., Carroll, J., Goldman, J. W., & Garon, E. B. (2017) · Clinical Lung Cancer · doi:10.1016/j.cllc.2017.06.004 · Cited by 26
Kang, M.-S., Park, C., Kim, S. H., Yoon, S. W., Suh, K. J., Kim, Y. J., Ock, C.-Y., Kim, M., Keam, B., Kim, T. M., et al. (2021) · Translational Lung Cancer Research · doi:10.21037/tlcr-20-893 · Cited by 26
Self-citationBersanelli, M., Tiseo, M., Artioli, F., Lucchi, L., & Ardizzoni, A. (2014) · PubMed · Cited by 25
Liu, Y., Jiang, H., Zhou, H., Ying, X., Wang, Z., Yang, Y., Xu, W., He, X., & Li, Y. (2017) · Oncology Letters · doi:10.3892/ol.2017.7656 · Cited by 25
Therapeutic strategies for afatinib‐resistant lung cancer harboring HER 2 alterations
Torigoe, H., Shien, K., Takeda, T., Yoshioka, T., Namba, K., Sato, H., Suzawa, K., Yamamoto, H., Soh, J., Sakaguchi, M., et al. (2018) · Cancer Science · doi:10.1111/cas.13571 · Cited by 25
Epidermal growth factor receptor (EGFR)-targeted therapies in mesothelioma
Chia, P. L., Scott, A. M., & John, T. (2019) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2019.1598374 · Cited by 25
van der Weijst, L., Lievens, Y. N., Schrauwen, W., & Surmont, V. F. M. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00715 · Cited by 25
Song, T., Yu, W., & Wu, S. (2014) · Asian Pacific Journal of Cancer Prevention · doi:10.7314/apjcp.2014.15.1.205 · Cited by 25
Afatinib in the treatment of head and neck squamous cell carcinoma
Ferrarotto, R., & Gold, K. A. (2013) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2014.858696 · Cited by 25
Cardiac safety of afatinib: a review of data from clinical trials
Ewer, M. S., Patel, K. P., O’Brien, D., & Lorence, R. M. (2015) · Cardio-Oncology · doi:10.1186/s40959-015-0006-7 · Cited by 25
Self-citationKoyama, N., Watanabe, Y., Iwai, Y., Kawamura, R., Miwa, C., Nagai, Y., Hagiwara, K., & Koyama, S. (2017) · Chemotherapy · doi:10.1159/000454944 · Cited by 25
O'Kane, G. M., Barnes, T. A., & Leighl, N. B. (2018) · Current Oncology · doi:10.3747/co.25.3796 · Cited by 25
Misra, P., & Singh, S. (2019) · Cancer Medicine · doi:10.1002/cam4.2112 · Cited by 25
Gomes, J., & Cruz, M. R. (2015) · OncoTargets and Therapy · doi:10.2147/ott.s75388 · Cited by 24
Lee, J. C., Jang, S. H., Lee, K. Y., & Kim, Y. (2013) · Cancer Research and Treatment · doi:10.4143/crt.2013.45.2.79 · Cited by 24
Ulivi, P. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17071186 · Cited by 24
Zhao, L., Fan, T., Shi, Z., Ding, C., Zhang, C., Yuan, Z., Sun, Q., Tan, C., Chu, B., & Jiang, Y. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113173 · Cited by 24
Testing EGFR with Idylla on Cytological Specimens of Lung Cancer: A Review
Caputo, A., D’Ardia, A., Sabbatino, F., Picariello, C., Ciaparrone, C., Zeppa, P., & D’Antonio, A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22094852 · Cited by 25
Recent Advances in the Transition-Metal-Free Synthesis of Quinazolines
Tamatam, R., & Shin, D. (2023) · Molecules · doi:10.3390/molecules28073227 · Cited by 24
van der Wekken, A. J., Kuiper, J. L., Saber, A., Terpstra, M. M., Wei, J., Hiltermann, T. J. N., Thunnissen, E., Heideman, D. A. M., Timens, W., Schuuring, E. M. D., et al. (2017) · PLoS ONE · doi:10.1371/journal.pone.0182885 · Cited by 24
Precision Oncology: Neither a Silver Bullet nor a Dream
Sánchez, N., Mills, G. B., & Shaw, K. R. M. (2017) · Pharmacogenomics · doi:10.2217/pgs-2017-0094 · Cited by 26
Patel, H., Pawara, R. H., & Surana, S. J. (2018) · Computational Biology and Chemistry · doi:10.1016/j.compbiolchem.2018.03.026 · Cited by 24
The in cis compound EGFR mutations in Chinese advanced non-small cell lung cancer patients
Li, M., Zhou, C., Yang, J., Lü, S., Zheng, D., Hu, J., Zeng, H., Lü, Y., Lu, K., Li, S., et al. (2019) · Cancer Biology & Therapy · doi:10.1080/15384047.2019.1595280 · Cited by 23
Self-citationAfatinib for the treatment of advanced non-small-cell lung cancer
Genova, C., Rijavec, E., Barletta, G., Burrafato, G., Biello, F., Bello, M. G. D., Coco, S., Truini, A., Alama, A., Boccardo, F., et al. (2014) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2014.902445 · Cited by 23
Irreversible EGFR-TKIs: dreaming perfection.
Landi, L. M., & Cappuzzo, F. (2013) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2218-6751.2012.12.05 · Cited by 25
Emerging treatment for advanced lung cancer withEGFRmutation
Inal, C., Yilmaz, E., Piperdi, B., Perez-Soler, R., & Cheng, H. (2015) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.2015.1058778 · Cited by 23
Machiels, J., Licitra, L. F., Haddad, R. I., Tahara, M., & Cohen, E. E. W. (2014) · BMC Cancer · doi:10.1186/1471-2407-14-473 · Cited by 23
Identification of a novel HER3 activating mutation homologous to EGFR-L858R in lung cancer
Umelo, I. A., Noeparast, M., Chen, G., Renard, M., Geers, C., Vansteenkiste, J., Giron, P., Wever, O. D., Teugels, E., & Grève, J. D. (2015) · Oncotarget · doi:10.18632/oncotarget.6585 · Cited by 23
Morán, T., Palmero, R., Provencio, M., Insa, A., Majem, M., Reguart, N., Bosch‐Barrera, J., Isla, D., Carcereny, E., Lee, C., et al. (2017) · Lung Cancer · doi:10.1016/j.lungcan.2017.03.009 · Cited by 23
Dercle, L., Connors, D. E., Tang, Y., Adam, S. J., Gönen, M., Hilden, P. D., Karovic, S., Maitland, M. L., Moskowitz, C. S., Kelloff, G. V., et al. (2018) · JCO Clinical Cancer Informatics · doi:10.1200/cci.17.00137 · Cited by 23
Lim, C., Wei, Y.-F., Tsai, M., Chen, K., Shih, J., & Yu, C.-J. (2018) · European Journal of Cancer · doi:10.1016/j.ejca.2018.07.128 · Cited by 23
Oda, N., Hotta, K., Ninomiya, K., Minami, D., Ichihara, E., Murakami, T., Yokoyama, T., Ichikawa, H., Chikamori, K., Takigawa, N., et al. (2018) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-018-3694-5 · Cited by 24
Novel drugs against non-small-cell lung cancer
Pirker, R. (2014) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000056 · Cited by 22
Progress of EGFR-TKI and ALK/ROS1 inhibitors in advanced non-small cell lung cancer.
Ge, L., & Shi, R. (2015) · PubMed · Cited by 22
Kobayashi, K., Naoki, K., Manabe, T., Masuzawa, K., Hasegawa, H., Yasuda, H., Kawada, I., Soejima, K., & Betsuyaku, T. (2018) · OncoTargets and Therapy · doi:10.2147/ott.s161745 · Cited by 22
Yin, X., Zhao, Z., Yin, Y., Shen, C., Chen, X., Cai, Z., Wang, J., Chen, Z., Yin, Y., & Zhang, B. (2020) · Clinical and Translational Science · doi:10.1111/cts.12957 · Cited by 22
Tourneau, C. L., Paolettí, X., Coquan, E., Sablin, M., Zoubir, M., & Tannock, I. F. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.53.5518 · Cited by 22
Alshami, J., Guiot, M., Owen, S. P., Kavan, P., Gibson, N. J., Solca, F., Cseh, A., Reardon, D. A., & Muanza, T. M. (2015) · Oncotarget · doi:10.18632/oncotarget.5297 · Cited by 22
Horn, L., Gettinger, S. N., Camidge, D. R., Smit, E. F., Janjigian, Y. Y., Miller, V. A., Pao, W. J., Freiwald, M., Fan, J., Wang, B., et al. (2017) · Lung Cancer · doi:10.1016/j.lungcan.2017.08.014 · Cited by 21
Self-citationHill, J., Jones, R. M., & Crich, D. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c01669 · Cited by 21
West, H., Oxnard, G. R., & Doebele, R. C. (2013) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbook_am.2013.33.e272 · Cited by 22
Oxnard, G. R. (2012) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2012-0254-ra · Cited by 21
Hickish, T., Cassidy, J., PROPPER, D. J., Chau, I., Falk, S. J., Ford, H. E. R., Iveson, T. J., Braun, M., Potter, V. A., Macpherson, I. R., et al. (2014) · European Journal of Cancer · doi:10.1016/j.ejca.2014.08.008 · Cited by 24
Targeted Therapies for the Treatment of Brain Metastases in Solid Tumors
Bohn, J., Pall, G., Stockhammer, G., & Steurer, M. (2016) · Targeted Oncology · doi:10.1007/s11523-015-0414-5 · Cited by 21
Looking back and to the future: Are we improving ‘cure’ in non-small cell lung cancer?
Walder, D., & O'Brien, M. E. R. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.01.006 · Cited by 21
Barrón, F., Cardona, A. F., Corrales, L., Tirado, L. A. R., Caballé‐Perez, E., Sanchez, G., Flores‐Estrada, D., Zatarain-Barrón, Z. L., & Arrieta, O. G. (2018) · Journal of Thoracic Disease · doi:10.21037/jtd.2018.03.106 · Cited by 21
Mu, Y., Xing, P., Hao, X., Wang, Y., & Li, J. (2019) · Cancer Management and Research · doi:10.2147/cmar.s221434 · Cited by 21
Xin, S., Zhao, Y., Wang, X., Huang, Y., Zhang, J., Guo, Y. Q., Li, J., Li, H.-L., Ma, Y., Chen, L., et al. (2015) · Scientific Reports · doi:10.1038/srep12675 · Cited by 21
Tokunaga, Y., Liu, D., Nakano, J., Zhang, X., Nii, K., Go, T., Huang, C., & Yokomise, H. (2015) · European Journal of Cancer · doi:10.1016/j.ejca.2015.05.013 · Cited by 21
The distinctive nature of adenocarcinoma of the lung
Roviello, G. (2015) · OncoTargets and Therapy · doi:10.2147/ott.s89225 · Cited by 22
Park, K., Cho, B. C., Kim, D., Ahn, M., Lee, S. Y., Gernhardt, D., Taylor, I. W., Campbell, A., Zhang, H., Giri, N., et al. (2014) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000275 · Cited by 21
Self-citationTargeting Epidermal Growth Factor Receptor in the Management of Lung Cancer
Mok, T. S. K., Lee, K., & Leung, L. K. S. (2013) · Seminars in Oncology · doi:10.1053/j.seminoncol.2013.12.010 · Cited by 20
Management of tyrosine kinase inhibitor resistance in lung cancer with EGFR mutation
Becker, K. D. (2014) · World Journal of Clinical Oncology · doi:10.5306/wjco.v5.i4.560 · Cited by 19
Chen, J. A., & Riess, J. W. (2020) · Journal of Thoracic Disease · doi:10.21037/jtd.2019.08.32 · Cited by 21
Xiao, J., Zhou, L., He, B., & Chen, Q. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.01531 · Cited by 23
Hsieh, P., Wu, Y., Huang, C.-Y., Yang, M.-C., Kuo, C., Tzeng, I., & Lan, C. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.869390 · Cited by 20
Normando, S. R. C., Cruz, F. M., & del Giglio, A. (2015) · Anti-Cancer Drugs · doi:10.1097/cad.0000000000000268 · Cited by 20
Umeguchi, H., Sueoka‐Aragane, N., Kobayashi, N., Nakamura, T., Sato, A., TAKEDA, Y., Hayashi, S., Sueoka, E., & Kimura, S. H. (2014) · Oncology Reports · doi:10.3892/or.2014.3560 · Cited by 20
Abdel-Rahman, O. M., & Elhalawani, H. M. (2015) · Future Oncology · doi:10.2217/fon.15.16 · Cited by 20
Barnfield, P. C., & Ellis, P. M. (2016) · Drugs · doi:10.1007/s40265-016-0628-6 · Cited by 20
Kudo, K., Ohashi, K., Makimoto, G., Higo, H., Kato, Y., Kayatani, H., Kurata, Y., Takami, Y., Minami, D., Ninomiya, T., et al. (2017) · Molecular Oncology · doi:10.1002/1878-0261.12063 · Cited by 21
Mann, H., Andersohn, F., Bodnar, C., Mitsudomi, T., Mok, T. S. K., Yang, J. C., & Hoyle, C. (2017) · Clinical Drug Investigation · doi:10.1007/s40261-017-0611-3 · Cited by 20
Self-citationEmerging paradigms in targeted treatments for Asian patients with NSCLC
Ke, E., Zhou, Q. H., & Wu, Y.-L. L. C. (2015) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2015.1040391 · Cited by 20
SHOC2 Is a Critical Modulator of Sensitivity to EGFR–TKIs in Non–Small Cell Lung Cancer Cells
Terai, H., Hamamoto, J., Emoto, K., Masuda, T., Manabe, T., Kuronuma, S., Kobayashi, K., Masuzawa, K., Ikemura, S., Nakayama, S., et al. (2020) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-20-0664 · Cited by 18
Tan, D. S. W., Kim, S., Ponce-Aix, S., Sequist, L. V. D., Smit, E. F., Yang, J. C., Hida, T., Toyozawa, R., Felip, E., Wolf, J., et al. (2022) · European Journal of Cancer · doi:10.1016/j.ejca.2022.05.023 · Cited by 19
Self-citationZhao, W., Song, A., Xu, Y., Wu, Q., Liu, C., Yin, J. C., Ou, Q., Wu, X., Shao, Y. W., & Zhao, X. (2023) · BMC Medicine · doi:10.1186/s12916-023-02768-z · Cited by 19
Management of Dermatologic Complications of Lung Cancer Therapies
Pugliese, S. B., Neal, J. W., & Kwong, B. Y. (2015) · Current Treatment Options in Oncology · doi:10.1007/s11864-015-0368-y · Cited by 19
EGFR Mutation Positive Stage IV Non-Small-Cell Lung Cancer: Treatment Beyond Progression
Assche, K. V., Ferdinande, L., Lievens, Y. N., Vandecasteele, K., & Surmont, V. F. M. (2014) · Frontiers in Oncology · doi:10.3389/fonc.2014.00350 · Cited by 19
Abdallah, S. M.-B., & Hirsh, V. (2018) · Current Oncology · doi:10.3747/co.25.3732 · Cited by 19
Self-citationAkher, F. B., Farrokhzadeh, A., & Soliman, M. E. S. (2018) · Chemistry & Biodiversity · doi:10.1002/cbdv.201800518 · Cited by 20
New therapeutic approaches to overcoming resistant EGFR exon 20 alterations
Li, A. M., Boichard, A., Felip, E., & Kurzrock, R. (2020) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2020.102990 · Cited by 20
Wang, L., Cao, Y., Ren, M., Chen, A., Cui, J., Sun, D., & Gu, W. (2017) · Clinical Therapeutics · doi:10.1016/j.clinthera.2016.12.008 · Cited by 19
Managing Acquired Resistance in EGFR-Mutated Non–Small Cell Lung Cancer
Forde, P. M., & Ettinger, D. S. (2021) · Default Digital Object Group · doi:10.1200/adn.21.200653 · Cited by 19
Trials to Overcome Drug Resistance to EGFR and ALK Targeted Therapies – Past, Present, and Future
Spaans, J. N., & Goss, G. D. (2014) · Frontiers in Oncology · doi:10.3389/fonc.2014.00233 · Cited by 19
Xu, J., Liu, X., Yang, S., Zhang, X., & Shi, Y. (2017) · OncoTargets and Therapy · doi:10.2147/ott.s142686 · Cited by 18
Matada, G. S. P., Dhiwar, P. S., Abbas, N., Singh, E., Ghara, A., Patil, R. B., & Raghavendra, N. M. (2022) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2022.132531 · Cited by 18
Molife, L. R., Rudman, S. M., Alam, S. M., Tan, D. S. W., Kristeleit, H., Middleton, G., PROPPER, D. J., Bent, L., Stopfer, P., Uttenreuther‐Fischer, M., et al. (2013) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-013-2286-7 · Cited by 18
Re, M. D., Vasile, E., Falcone, A., Danesi, R., & Petrini, I. (2014) · Expert Review of Molecular Diagnostics · doi:10.1586/14737159.2014.908120 · Cited by 18
Afatinib: A first-line treatment for selected patients with metastatic non-small-cell lung cancer
Engle, J. A., & Kolesar, J. (2014) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp130654 · Cited by 18
Arriola, E., Reguart, N., Artal, A., Cobo, M., García‐Campelo, R., Esteban, E., Rodríguez, M. C., & García-Muret, M. P. (2014) · Future Oncology · doi:10.2217/fon.14.214 · Cited by 18
Zhang, Y., Zhang, Z., Huang, X., Kang, S., Chen, G., Wu, M., Miao, S., Huang, Y., Zhao, H., & Zhang, L. (2016) · Clinical Lung Cancer · doi:10.1016/j.cllc.2016.09.006 · Cited by 18
Novel EGFR Inhibitors in Non-small Cell Lung Cancer: Current Status of Afatinib
Liao, B.-C., Lin, C., & Yang, J. C. (2017) · Current Oncology Reports · doi:10.1007/s11912-017-0560-2 · Cited by 18
Self-citationYamaguchi, O., Kaira, K., Mouri, A., Shiono, A., Hashimoto, K., Miura, Y., Nishihara, F., Murayama, Y., Kobayashi, K., & Kagamu, H. (2019) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-019-03790-w · Cited by 20
Combating Acquired Resistance to Tyrosine Kinase Inhibitors in Lung Cancer
Lovly, C. M. (2015) · American Society of Clinical Oncology Educational Book · doi:10.14694/edbook_am.2015.35.e165 · Cited by 19
Management of pulmonary toxicity associated with targeted anticancer therapies
Teuwen, L.-A. M. N., den Mooter, T. V., & Dirix, L. Y. (2015) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2015.1080687 · Cited by 18
Lee, V. H.-F., Leung, D. K. C., Choy, T., Lam, K. O., Lam, P. K. L., Leung, T., & Kwong, D. L. �. (2016) · BMC Cancer · doi:10.1186/s12885-016-2201-9 · Cited by 18
Pauw, I. D., Wouters, A., den Bossche, J. V., Peeters, M., Pauwels, P., Deschoolmeester, V., Vermorken, J. B., & Lardon, F. (2016) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2016.06.014 · Cited by 17
Hoshi, H., Hiyama, G., Ishikawa, K., Inageda, K., Fujimoto, J., Wakamatsu, A., Togashi, T., Kawamura, Y., Takahashi, N., Higa, A., et al. (2016) · Oncology Reports · doi:10.3892/or.2016.5227 · Cited by 18
Metadata
- Authors
- Miller, V. A., Hirsh, V., Cadranel, J., Chen, Y.-M., Park, K., Kim, S.-W., Zhou, C., Su, W.-C., Wang, M., Sun, Y., Heo, D. S., Crino, L., Tan, E.-H., Chao, T.-Y., Shahidi, M., Cong, X. J., Lorence, R. M., & Yang, J. C.-H.
- Affiliations
- Memorial Sloan Kettering Cancer Center (US)
- McGill University Health Centre (CA)
- Assistance Publique – Hôpitaux de Paris (FR)
- Taipei Veterans General Hospital (TW)
- Samsung Medical Center (KR)
- Asan Medical Center (KR)
- Tongji University (CN)
- National Cheng Kung University Hospital (TW)
- Peking Union Medical College Hospital (CN)
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- Seoul National University Hospital (KR)
- National Cancer Centre Singapore (SG)
- Taipei Medical University-Shuang Ho Hospital (TW)
- Boehringer Ingelheim (United Kingdom) (GB)
- Boehringer Ingelheim (United States) (US)
- National Taiwan University (TW)
- Corresponding author
- Yang, James Chih-Hsin
- ORCID
- Venue
- The Lancet Oncology
- Publisher
- Elsevier BV
- Published
- 2012-05
- Volume
- 13
- Issue
- 5
- Pages
- 528-538
- ISSN
- 1470-2045 (ISSN-L)
- OpenAlex
- W2152905269
- Cited by
- 961
- References
- 29
- Citations by year
- 2026: 14 · 2025: 14 · 2024: 28 · 2023: 38 · 2022: 33 · 2021: 46 · 2020: 50 · 2019: 57 · 2018: 70 · 2017: 103 · 2016: 99 · 2015: 125 · 2014: 139 · 2013: 107 · 2012: 37
- FWCI
- 105.26
- Type
- journal article
- Language
- en
- Update notices
- erratum (2012-05-01)
- Open access
- closed
- Locations
- The Lancet Oncology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
- Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
- Keywords
- afatinib, non-small cell lung cancer, lung adenocarcinoma, EGFR tyrosine kinase inhibitors, erlotinib, gefitinib, EGFR mutation, EGFR inhibitor resistance, second-line therapy, overall survival, progression-free survival, best supportive care, targeted therapy
- MeSH terms
- Erlotinib Hydrochloride, Gefitinib, Afatinib, Adenocarcinoma, Adult, Aged, Aged, 80 and over, Antineoplastic Agents, Antineoplastic Combined Chemotherapy Protocols, Double-Blind Method, Female, Humans, Lung Neoplasms, Male, Middle Aged, Quinazolines, Protein Kinase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
